Innovent Biologics, Inc.

1801

KYG4818G1010

Innovent Biologics, Inc. is a China-based biopharmaceutical company. The Company's main products include PD-1 antibody; bevacizumab (Avastin) biosimilar, IBI-305; rituximab (MabThera/Rituxan) biosimilar, IBI-301; and adalimumab (Humira) biosimilar, IBI-303.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Innovent Biologics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

33.15 CNY

Average target price

51.42 CNY

Spread / Average Target

+55.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INNOVENT BIOLOGICS, INC.	-18.83%	7.43B
CSL LIMITED	-4.17%	86.99B
SAMSUNG BIOLOGICS CO.,LTD.	+4.34%	40.68B
BIOGEN INC.	-24.18%	28.61B
UCB	+51.27%	24.1B
BIOMARIN PHARMACEUTICAL INC.	-5.03%	17.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-32.11%	13.72B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-5.10%	12.49B
INCYTE CORPORATION	-14.37%	12B
SWEDISH ORPHAN BIOVITRUM AB	-3.22%	7.94B

Biopharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-16 am EDT			5-day change	1st Jan Change
34.7 ^HKD	-3.21%		-8.80%	-18.83%

Apr. 02	Hutchmed endometrial cancer treatment application accepted for review	AN
Apr. 02	Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	MT

Hutchmed endometrial cancer treatment application accepted for review	Apr. 02	AN
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	Apr. 02	MT
HSBC in special payout on Canada sale; Astra FDA win	Apr. 02	AN
Innovent Biologics New Cancer Drug Gets NDA from Chinese Authority	Apr. 02	MT
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	Apr. 02	CI
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application	Apr. 02	CI
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows	Mar. 20	MT
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024	Mar. 06	CI
China Accepts Innovent's Second Drug Application for Lung Cancer Treatment; Shares Slide 6%	Mar. 05	MT
Anheart Therapeutics and Innovent Announces China?s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer	Mar. 04	CI
Nomura Adjusts Innovent Biologics’ Price Target to HK$55.31 From HK$54.51, Keeps at Buy	Feb. 26	MT
Innovent Biologics' Phase 3 Trial for Thyroid Eye Disease Treatment Meets Primary Endpoints	Feb. 19	MT
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease	Feb. 19	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	Feb. 15	RE
Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee	Feb. 09	CI
Innovent Biologics’ New Drug Application for Weight Management Drug Accepted by Chinese Regulator	Feb. 07	MT
Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China	Feb. 07	CI
Innovent Biologics Posts 65% Revenue Growth in Q4 of 2023	Feb. 06	MT
Innovent Biologics, Inc. Reports Revenue Results for the Fourth Quarter of 2023	Feb. 06	CI
Innovent Biologics Names New CFO	Feb. 05	MT
Innovent Biologics, Inc. Announces Chief Financial Officer Changes	Feb. 05	CI
Innovent Bio's Weight Management Drug Trial Meets Primary and Secondary Endpoints	Jan. 09	MT
Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints	Jan. 08	CI
Innovent Biologics, Inc. and Sanegene Bio USA Inc. Enter Strategic Collaboration to Develop Sirna Drug for the Treatment of Hypertension	Dec. 26	CI